A turn in the road: How studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity.
D000215:Acylation; D000217:Acyltransferases / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism*; D000818:Animals; D002417:Cattle; D002518:Ceramides / Q000378:metabolism; D018076:DNA, Complementary; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors; D006801:Humans; D008247:Lysosomes / Q000201:enzymology*; D051379:Mice; D015394:Molecular Structure; D009025:Morpholines / Q000737:chemistry / Q000494:pharmacology*; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D015398:Signal Transduction; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000378:metabolism
D002518:Ceramides; D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D009025:Morpholines; C064769:N-acetylsphingosine; C033110:RV 538; D000217:Acyltransferases; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase; D010741:Phospholipases A; D054467:Phospholipases A2; C401297:phospholipase A2, group XV; D013110:Sphingosine